Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLY-2608 + fulvestrant versus capivasertib + fulvestrant in PIK3CA-mutated HR-positive/HER2-negative advanced or metastatic breast cancer
NL-OMON60341Phase 3Recruiting
- Sponsor
- Relay Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zovegalisib, capivasertib and fulvestrant in breast cancer, sponsored by Relay Therapeutics. Started Dec 2025; status: recruiting.
02
Drugs
zovegalisibcapivasertibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60341.